Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04149821
Title Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.